Transition from Primary Raynaud's Phenomenon to Secondary Raynaud's Phenomenon Identified by Diagnosis of an Associated Disease: Results of Ten Years of Prospective Surveillance
Overview
Authors
Affiliations
Objective: To assess the early signs, risk factors, and rate of transition from primary Raynaud's phenomenon (primary RP) to secondary RP.
Methods: A clinical sample of 307 consecutive patients with RP was included in a prospective followup study. After an initial screening, 244 patients were classified as having primary RP, of whom 236 were followed up for a mean +/- SD of 11.2 +/- 3.9 years. Patients classified according to the screening as having suspected secondary RP underwent an extended screening program annually until transition to secondary RP occurred.
Results: The initial prevalence of secondary RP was 11%. The annual incidence of transition to suspected secondary RP was 2%, and the annual incidence of transition to secondary RP was 1%. Overall, 46 patients were classified as having suspected secondary RP, and 23 of these later were classified as having secondary RP. Older age at onset of RP (hazard ratio 2.59, 95% confidence interval [95% CI] 1.40-4.80), shorter duration of RP at enrollment (hazard ratio 0.87, 95% CI 0.81-0.94), and abnormal findings on thoracic outlet test (hazard ratio 2.69, 95% CI 1.12-6.48) were associated with an increased risk for transition to secondary RP. Compared with patients with suspected secondary RP, those diagnosed as having secondary RP had a higher number and earlier occurrence of pathologic findings. Furthermore, antinuclear antibodies at a titer of > or = 1:320 and positive findings in specific serologic subsets were associated with a significantly increased risk for developing a connective tissue disease.
Conclusion: Patients diagnosed initially as having primary RP may actually comprise 1 of 3 groups: those with idiopathic RP, those with a rather benign disease course, and those with a more severe course of the disease.
Fabian B, Csiki Z, Bugan A Clin Rheumatol. 2024; 43(12):3963-3972.
PMID: 39392515 PMC: 11582172. DOI: 10.1007/s10067-024-07175-0.
Amor-Dorado J, Martin-Sanz E, Franco-Gutierrez V, Urruticoechea-Arana A, Garcia-Arumi A, Racines-Alava E J Clin Med. 2023; 12(9).
PMID: 37176671 PMC: 10179300. DOI: 10.3390/jcm12093232.
Mueller M, Gschwandtner M, Emminger W, Kiener H, Schnaubelt S, Giurgea G RMD Open. 2023; 9(1).
PMID: 36972928 PMC: 10069575. DOI: 10.1136/rmdopen-2023-003077.
Andraos R, Ahmad A, Eriksson P, Dahlstrom O, Wirestam L, Dahle C Lupus Sci Med. 2022; 9(1).
PMID: 36581379 PMC: 9806068. DOI: 10.1136/lupus-2022-000732.
Anyfanti P, Angeloudi E, Dara A, Arvanitaki A, Bekiari E, Kitas G Life (Basel). 2022; 12(8).
PMID: 36013346 PMC: 9410266. DOI: 10.3390/life12081167.